ProCE Banner Activity

Phase III ADVANCE: 96-Wk Primary Efficacy Analysis of DTG + FTC/(TAF or TDF) vs EFV/FTC/TDF in ART-Naive PWH in South Africa

Slideset Download
Conference Coverage
Noninferiority of first-line DTG-based vs EFV-based regimens maintained through Week 96, with significantly greater weight gain observed in PWH receiving DTG + FTC/TAF.

Released: July 10, 2020

Expiration: July 09, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Educational grant provided by:

Gilead

Merck Sharp & Dohme Corp.

ViiV Healthcare

Partners

AIDS 2020

ProCE Banner

IAS 2018

ProCE Banner